image
Healthcare - Medical - Devices - NASDAQ - US
$ 13.47
0 %
$ 572 M
Market Cap
-17.96
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SIBN stock under the worst case scenario is HIDDEN Compared to the current market price of 13.5 USD, SI-BONE, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SIBN stock under the base case scenario is HIDDEN Compared to the current market price of 13.5 USD, SI-BONE, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SIBN stock under the best case scenario is HIDDEN Compared to the current market price of 13.5 USD, SI-BONE, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SIBN

image
$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
167 M REVENUE
20.37%
-35.2 M OPERATING INCOME
24.89%
-30.9 M NET INCOME
28.67%
-12.4 M OPERATING CASH FLOW
33.60%
12.6 M INVESTING CASH FLOW
121.11%
1.96 M FINANCING CASH FLOW
-97.85%
49 M REVENUE
21.47%
-5.49 M OPERATING INCOME
28.02%
-4.5 M NET INCOME
31.63%
1.18 M OPERATING CASH FLOW
290.07%
4.34 M INVESTING CASH FLOW
15.07%
-78 K FINANCING CASH FLOW
-50.32%
Balance Sheet SI-BONE, Inc.
image
Current Assets 208 M
Cash & Short-Term Investments 150 M
Receivables 27.5 M
Other Current Assets 30.3 M
Non-Current Assets 22.7 M
Long-Term Investments 0
PP&E 22.4 M
Other Non-Current Assets 300 K
65.11 %11.92 %13.14 %9.70 %Total Assets$230.4m
Current Liabilities 27.1 M
Accounts Payable 6.49 M
Short-Term Debt 1.15 M
Other Current Liabilities 19.5 M
Non-Current Liabilities 36.3 M
Long-Term Debt 1.76 M
Other Non-Current Liabilities 34.6 M
10.22 %30.71 %54.48 %Total Liabilities$63.5m
EFFICIENCY
Earnings Waterfall SI-BONE, Inc.
image
Revenue 167 M
Cost Of Revenue 35.1 M
Gross Profit 132 M
Operating Expenses 167 M
Operating Income -35.2 M
Other Expenses -4.34 M
Net Income -30.9 M
200m200m150m150m100m100m50m50m00(50m)(50m)167m(35m)132m(167m)(35m)4m(31m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
79.03% GROSS MARGIN
79.03%
-21.08% OPERATING MARGIN
-21.08%
-18.49% NET MARGIN
-18.49%
-18.51% ROE
-18.51%
-13.41% ROA
-13.41%
-17.24% ROIC
-17.24%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis SI-BONE, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -30.9 M
Depreciation & Amortization -1.06 M
Capital Expenditures -10.5 M
Stock-Based Compensation 25.9 M
Change in Working Capital 0
Others -6.32 M
Free Cash Flow -22.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets SI-BONE, Inc.
image
Wall Street analysts predict an average 1-year price target for SIBN of $21.3 , with forecasts ranging from a low of $18 to a high of $32 .
SIBN Lowest Price Target Wall Street Target
18 USD 33.63%
SIBN Average Price Target Wall Street Target
21.3 USD 58.02%
SIBN Highest Price Target Wall Street Target
32 USD 137.56%
Price
Max Price Target
Min Price Target
Average Price Target
353530302525202015151010May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership SI-BONE, Inc.
image
Sold
0-3 MONTHS
1.18 M USD 4
3-6 MONTHS
382 K USD 4
6-9 MONTHS
407 K USD 4
9-12 MONTHS
258 K USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript seekingalpha.com - 1 month ago
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates Si-Bone (SIBN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.27 per share a year ago. zacks.com - 1 month ago
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024 Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024 globenewswire.com - 1 month ago
Bruker Appoints Laura Francis to its Board of Directors BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (Nasdaq: SIBN), a medical device company s. businesswire.com - 1 month ago
Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy? Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025 SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. globenewswire.com - 2 months ago
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.71%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 64.7% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 4 months ago
Wall Street Analysts See an 83.56% Upside in Si-Bone (SIBN): Can the Stock Really Move This High? The consensus price target hints at an 83.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 4 months ago
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. globenewswire.com - 4 months ago
SI-BONE, Inc. (SIBN) Q3 2024 Earnings Call Transcript SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - BofA Securities Young Li - Jefferies Drew Ranieri - Morgan Stanley Caitlin Cronin - Canaccord Richard Newitter - Truist Securities Operator Good afternoon, and welcome to SI-BONE's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 5 months ago
Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates Si-Bone (SIBN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago. zacks.com - 5 months ago
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024. globenewswire.com - 5 months ago
8. Profile Summary

SI-BONE, Inc. SIBN

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 572 M
Dividend Yield 0.00%
Description SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Contact 471 El Camino Real, Santa Clara, CA, 95050 https://si-bone.com
IPO Date Oct. 17, 2018
Employees 349
Officers Mr. Troy Wahlenmaier Senior Vice President of US Sales Ms. Joyce Goto Vice President & Corporate Controller Mr. Jeffrey W. Dunn Executive Chairman Dr. Scott A. Yerby Senior Vice President of Engineering & Chief Technology Officer Mr. Anshul Maheshwari Chief Financial Officer Saqib Iqbal Director of FP&A and Investor Relations Mr. Anthony J. Recupero President of Commercial Operations Ms. Laura A. Francis MBA Chief Executive Officer & Director Mr. Michael A. Pisetsky J.D. Chief Business & Legal Affairs Officer, Secretary and General Counsel